Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 718.95M | $ 661.82M | $ 607.52M | $ 667.24M | $ 579.77M |
| Gross Profit | $ 644.39M | $ 583.91M | $ 523.74M | $ 580.02M | $ 504.71M |
| Operating Income | $ -36.86M | $ 81.67M | $ -5.27M | $ 46.12M | $ 86.03M |
| EBITDA | $ -49.03M | $ 178.28M | $ 90.04M | $ 153.36M | $ 129.19M |
| Net Income | $ -38.55M | $ 73.86M | $ 1.32M | $ 60.71M | $ 53.42M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 308.67B | $ 453.61M | $ 254.87M | $ 461.33M | $ 339.68M |
| Total Assets | $ 1.45T | $ 1.37B | $ 1.28B | $ 1.70B | $ 1.69B |
| Total Debt | $ 30.36B | $ 34.27M | $ 41.53M | $ 444.76M | $ 427.03M |
| Net Debt | $ -98.08B | $ -35.06M | $ -33.53M | $ 351.64M | $ 223.59M |
| Total Liabilities | $ 390.93B | $ 332.34M | $ 356.16M | $ 816.30M | $ 873.30M |
| Stockholders' Equity | $ 1.06T | $ 1.04B | $ 921.52M | $ 886.20M | $ 815.85M |
| Cash Flow | |||||
| Free Cash Flow | $ 45.99M | $ 171.23M | $ 110.53M | $ 116.41M | $ 125.08M |
| Operating Cash Flow | $ 47.33M | $ 171.95M | $ 111.08M | $ 116.83M | $ 127.13M |
| Investing Cash Flow | $ 4.11M | $ -189.87M | $ 268.73M | $ -216.66M | $ -81.91M |
| Financing Cash Flow | $ 9.13M | $ 12.19M | $ -397.88M | $ -10.48M | $ -130.42M |